Gregory Huhn, MD, MPHTM

Attending Physician
The Ruth M. Rothstein CORE CENTER

Disclosure(s): Eli Lilly: Advisor/Consultant, Grant/Research Support; Gilead: Advisor/Consultant, Grant/Research Support; Jannsen: Advisor/Consultant, Grant/Research Support; Merck: Advisor/Consultant; Viiv: Advisor/Consultant, Grant/Research Support

Poster(s):

• 1466 - Antiretroviral (ART) Virologic Suppression (VS) and Patient Reported Outcomes (PROs) at 6 Months in the Clinical Opportunities and Management to Exploit Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) an Asynchronous Connection Key (COMEBACK) Study
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 2087 - Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET